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a b s t r a c t
Mitochondrial diseases may cause a wide range of central and peripheral nervous system
disorders, as well as muscle disorders. The diagnostic workup routinely includes
electrophysiological, morphological, neuroimaging and genetic studies. In some cases,
the diagnosis may be ascertained only when mitochondrial DNA (mtDNA) examination
in the muscle is performed. We report on a case of a 24-year-old woman, with a 7-year
history of slowly progressive cerebellar syndrome and bilateral ptosis. Mitochondrial ence-
phalomyopathy was suspected, based on the clinical picture and results of examinations,
but the typical red ragged ﬁbers were not found in the muscle biopsy. The results of
molecular analysis of mtDNA showed a mtDNA deletion in the muscle and, on a level
detectable only with polymerase chain reaction method, in blood leukocytes. This case
emphasizes the important role of mtDNA studies in muscle in nonspeciﬁc multisystem
mitochondrial disorders, even without clinical muscle involvement.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Mitochondria are organelles involved in cellular energy
production, which contain their own DNA (mtDNA) encoding
a small number of essential polypeptides of the oxidative
phosphorylation system (OXPHOS). The coding sequences for
2 rRNAs, 22 tRNAs and 13 polypeptides are contiguous and
without introns [1]. However, most of the 88 protein subunits
of the mitochondrial respiratory chain (RC) complexes as well* Corresponding author at: Klinika Neurologii, Warszawski Uniwersyte
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http://dx.doi.org/10.1016/j.pjnns.2013.09.003as the mtDNA replication and most of the expression systems
are encoded by the nuclear genome. Thus, the proper
operation of the respiratory chain depends on interactions
between numerous genes. Mutations in nuclear DNA are
transmitted according to Mendelian rules. They occur in genes
encoding RC subunits and in genes encoding assembly and
auxiliary factors of the RC as well as proteins that affect
maintenance and expression of mtDNA or that have functions
indirectly linked to OXPHOS [2]. Until now more than 200
mtDNA point mutations, numerous mtDNA deletions as wellt Medyczny, ul. Banacha 1a, 02-097 Warszawa, Poland.
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described [3]. However, it is still impossible to establish the
genetic defect in 80–95% of patients suspected of having a
mitochondrial disorder [4].
Mitochondrial disorders are a heterogeneous group of
multi-system disorders resulting from impaired OXPHOS [5].
They may affect multiple organs, but the clinical manifesta-
tions vary in respect to age of onset, course and disease
severity. Symptoms are diverse and often non-speciﬁc [6,7],
making it difﬁcult to establish a precise genotype–phenotype
correlation and obtain a deﬁnite diagnosis [8,9]. The true
prevalence of mitochondrial disorders is difﬁcult to assess. It is
estimated that up to 9.2 in 100,000 adults aged less than 65
years may be affected [9]. At the genetic level, mitochondrial
disorders may result from mutations either in nuclear genes or
in mitochondrial DNA (mtDNA). Therefore, the recognition of
mitochondrial disorders remains challenging and diagnostic
procedures require a wide range of investigations.
In the diagnostic work-up of mitochondrial disorders the
most important ﬁrst step is the precise recognition of the
patient's symptoms and signs. Then, the various laboratory
tests, electrophysiological studies (electromyography, nerve
conduction studies and electroencephalography) and neuro-
imaging studies including magnetic resonance spectroscopy
may be applied. Usually, during further investigation, skeletal
muscle or skin biopsies are performed [10–12]. This makes it
possible to obtain tissues for morphological, biochemical and
supplementary genetic studies.
2. Case report
We present a case report of a 24-year-old woman, a student of
psychology, with a 7-year history of ataxia with slurring and
scanned speech, and with unremarkable family history. She
was referred to the Department of Neurology, Medical
University of Warsaw for the ﬁrst time when she was 17
years old. The ﬁrst symptoms – arm tremor and difﬁculties in
pronouncing words – occurred when she was 14 years old and
slowly progressed. The patient's mother reported compulsory
laughter and crying occurring also for 3 years. When she was
16, she started complaining of progressive difﬁculties with
stability and nausea with vomiting.Fig. 1 – (A) MRI. Diffuse hyperintense changes in white matter o
changes in white matter of hemispheres, in cerebellar hemisphThe neurological examination showed bilateral ptosis,
more pronounced in the left eyelid, pseudobulbar syndrome
and cerebellar syndrome (scanned speech, tremor of the head,
intention tremor of hands, with slight positional tremor,
ataxia of upper and lower extremities, walking with slightly
widened base). There was no signiﬁcant cognitive impairment.
During the ﬁrst hospitalization, the diagnostic methods
including laboratory tests in blood and cerebrospinal ﬂuid,
neuroimaging and electrophysiological examinations were
used. Slight hypocalcemia (2.16 mmol/L; normal range 2.2–
2.75 mmol/L) and a decreased level of magnesium (0.67 mmol/
L; normal range 0.7–1) were found in routine laboratory tests.
The parathormone level was decreased (11.97 pg/mL; normal
range 15–95 pg/mL), so hypoparathyroidism was diagnosed.
The level of lactic acid in blood was normal. However, an
elevated level of protein (155 mg/dL) with a normal level of
glucose and normal cytosis in cerebrospinal ﬂuid (CSF) was
found. Densitometry of the lumbar spine revealed the ﬁrst
symptoms of decalciﬁcation and prophylaxis of osteoporosis
was initiated. Cardiomyopathy and cardiac arrhythmias were
excluded by echocardiography and 24-h ECG tests. Audiologi-
cal tests demonstrated signiﬁcant sensorineural hearing loss
in the right ear. Ophthalmologic examination excluded
retinitis pigmentosa. Electrophysiological studies revealed
normal conduction parameters in peripheral nerves and
normal motor unit potentials in muscles. EEG showed
generalized discharges of delta waves 3 Hz and theta waves
4–7 Hz with sporadic sharp waves. Magnetic resonance
imaging (MRI) of the brain disclosed diffuse involvement of
the white matter (Fig. 1A and B). Magnetic resonance
spectroscopy (MRS) revealed a high concentration of lactates
in white matter of both hemispheres, in basal ganglia and in
cerebellar hemispheres. The levels of N-acetylaspartate and
choline were low.
Viral infections (Epstein-Barr virus, cytomegalovirus, her-
pes simplex virus), mycosis and neuroboreliosis were excluded
using appropriate tests as well as some forms of leucoence-
phalopathy as metachromatic leukodystrophy, adrenoleuko-
dystrophy and Krabbe disease.
The history of slowly progressed ataxia with scanned
speech and arms tremor, bilateral ptosis, pseudobulbar
syndrome with increased level of protein in cerebrospinal
ﬂuid, diffuse involvement of the white matter showed in MRIf both hemispheres (arrows). (B) MRI. Diffuse hyperintense
eres (arrows) and in basal ganglia.
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the diagnosis of mitochondrial encephalomyopathy. The next
step in diagnosis was muscle biopsy to ﬁnd ragged-red ﬁbers.
The patient was given coenzyme Q10 and supplements of
calcium and vitamin D3.
2.1. Muscle biopsy
Skeletal muscle biopsy of the quadriceps was performed under
local anaesthesia. Cryostat sections of fresh-frozen muscle
were stained with routine histological and histochemical
methods. Another part of the muscle was routinely prepared
for electron microscopy [13]. Moreover, respiratory chain
complex activity in the muscle homogenate was checked
with reference to the activity of citrate synthase.
Minor nonspeciﬁc myopathic changes were detected in
light microscopy, with no typical ragged-red ﬁbers (Fig. 2A
and B). In electron microscopy, small collections of abnormal
mitochondria with irregular cristae were detected in some
ﬁbers (Fig. 2C and D). Additionally, biochemical studies of
the respiratory chain complexes showed only a slight and
insigniﬁcant reduction in complex IV activity.
2.2. Molecular analysis
Polymerase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) tests for common mitochondrial DNA
point mutations: 3243A>G, 8344A>G, 8993T>G and 8993T>C
were performed as described in our previous paper [14].Fig. 2 – (A) Gomori trichrome 200T. Fiber with abnormal reddish 
increased activity of SDH in some fibers (arrow). (C) ME 20,000T
50,000T. Mitochondria with irregular cristae (arrow).A PCR test for the so-called common deletion of 4977 bp
was performed as described previously by Soong and Arnheim
[15]. Long PCR with primers located in the mtDNA major arc
(forward primer 6730–6750, reverse primer 16,545–16,526) was
performed using the Expand Long template PCR System
(ROCHE). PCR was carried out in 25 mL volume consisting of
2.5 mL 10 PCR number 2 buffer, 12.5 mM of each dNTP, 1.875U
polymerase, 6 nM of each primer and 100 ng of DNA template.
PCR was performed at 94 8C for 2 min, 10 cycles at 94 8C for 10 s,
58 8C for 30 s, 68 8C for 8 min and 25 cycles at 94 8C for 10 s,
58 8C for 30 s, 688 for 8 min + 20 s per cycle and ﬁnal elongation
at 68 8C for 20 min. For Southern analysis, total DNA (1000–
1200 ng) were separately digested with BamHI and PvuII
overnight at 37 8C. After electrophoresis in 0.8% agarose gel,
digested DNA samples were transferred onto Hybond mem-
brane and hybridized with previously labeled with 32P probe,
complementary to the D-loop region of mitochondrial DNA.
Restriction mapping of the long PCR product was performed
using BclI, HpaI, SnaBI, AvaI and EcoRV restriction enzymes. The
PCR product obtained with primers amplifying the region
7349–14928 [16] encompassing the deletion borders was
sequenced.
Molecular analysis performed on DNA isolated from
peripheral blood for common mitochondrial DNA point
mutations: 3243A>G, 8344A>G, 8993T>G and 8993T>C gave
negative results as did a PCR test for the so-called common
deletion of 4977 bp. Long PCR with primers located in the
mtDNA major arc performed on DNA isolated from peripheral
blood was positive suggesting a deletion greater than 6 kbrim (arrow). (B) Succinic dehydrogenase (SDH) 200T. Slightly
. Accumulation of abnormal mitochondria (arrow). (D) ME
Fig. 3 – Long polymerase chain reaction for blood leukocyte
DNA.
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was negative for the blood sample.
Deletion screening was repeated for DNA isolated from
muscle biopsy. Southern analysis revealed the existence of a
single large mtDNA deletion in muscle with 24% hetero-
plasmy. Long PCR product mapping, followed by sequencing of
the PCR product comprising the deletion borders, enabled us to
determine the precise deletion size. It has a length of 6976
nucleotides located between nucleotides 7823 and 14,799 and
contains direct imperfect border repeats of 12 nucleotides
(Fig. 4). This result conﬁrmed the diagnosis of a mitochondrial
encephalomyopathy.
Long PCR analysis was performed for the patient's mother
peripheral blood DNA with a negative result. The PCR test for
the common deletion and Southern hybridization were
performed for patient's brother. We also carried out the PCR
with primers comprising the patient's deletion borders. All
methods gave negative results.Fig. 4 – Determination of deleti3. Discussion
The ubiquitous nature of mtDNA and the peculiar rules of
mitochondrial genetics contribute to explaining the extraordi-
nary clinical heterogeneity of mitochondrial disorders. Howev-
er, due to the fact that the muscle and nerve tissues are highly
dependent on oxidative phosphorylation, they are usually
severely affected. According to the recently published guide-
lines by Wong et al. [4] in the ﬁrst diagnostic step the most
common point mutations and large scale deletions should be
checked. The most commonly used mtDNA samples are from
blood leukocytes, however, according to the literature, the
muscle tissue is the best one for screening for mtDNA
rearrangements [10].
Deletions of the mtDNA, ﬁrst described by Holt et al. in 1988
[11], are mostly heterogeneous and vary in length and location.
The so-called common deletion encompasses a 4977 bp
fragment and includes several tRNA and protein coding genes
[3]. Usually the deletions are associated with the chronic
progressive external ophthalmoplegia (CPEO), Kearns-Sayre
syndrome (KSS) and Pearson marrow-pancreas syndrome (PS).
CPEO is characterized by progressive external ocular muscle
impairment accompanied very often by ptosis. Kearns-Sayre
syndrome usually begins in the second decade of life, and apart
from progressive external ophthalmoplegia, pigmentary reti-
nopathy as well as cerebellar ataxia, cardiac conduction defects
and elevated cerebrospinal ﬂuid protein concentration occur. In
contrast, Pearson syndrome is associated with multisystem
manifestations such as sideroblastic anaemia, pancytopenia,
exocrine pancreatic insufﬁciency, malabsorption, nephropathy
and hepatopathy [10]. Moreover, mtDNA deletions have also
been described in many other conditions such as deafness and
diabetes as well as in neurodegenerative disorders [3].
Because of their heterogeneity, it is difﬁcult to describe
characteristic symptoms for mtDNA deletions. Our patient
presented some features typical for Kearns-Sayre syndrome:
cerebellar syndrome, mild ptosis and elevated level of protein
in cerebrospinal ﬂuid. However, retinitis pigmentosa and
cardiac conduction defects were excluded and RRF were noton borders by sequencing.
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patient has not been described so far.
Yamashita et al. [12] reported a group of 136 patients with
mtDNA deletions and with the predominance of CPEO and KSS
in clinical manifestations. The length and location of the
deletions were very heterogeneous. Moreover, the length of
the deletion and number of deleted tRNA genes were directly
correlated with the earlier onset of the disease and with the
more severe involvement of the central nervous system [12].
The exact pathological mechanism is not known, but it is
thought that mtDNA rearrangements are caused by inappro-
priate mechanisms of mtDNA repair processes [3].
The presented case emphasizes the role of mtDNA studies
in muscle in the diagnosis of atypical multisystem mitochon-
drial disorders, even without evident clinical muscle involve-
ment. The results of molecular analysis of mitochondrial DNA
show the presence of single, large deletion in the mtDNA in the
patient's muscle and, on a level detectable only by PCR
methods, in blood leukocytes. This is a frequent situation for
large mtDNA deletions, which are often at a low level or even
undetectable in blood. The percentage of mutated mtDNA
molecules in the patient's muscle biopsy is rather moderate.
This is in agreement with the histopathology, which has
shown only slight accumulation of mitochondria with no
typical ragged-red ﬁbers, and with slightly increased succinate
dehydrogenase activity. Negative deletion screening of the
patient's mother and brother is concordant with the sporadic
rather than inherited character of single mitochondrial
deletions. Hypoparathyroidism was the additional feature,
as it is sometimes reported in encephalomyopathies.
The case of our patient conﬁrms the necessity of molecular
analysis of mtDNA in the patient's muscle in uncertain
diagnosis. It points out that the diagnosis of mitochondrial
disorder requires various investigations and neurological,
cardiological, endocrine and ophthalmological follow-up is
advised.
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